This way forward to starting XENPOZYME

STARTING XENPOZYME

    Infusion bag icon with text stating XENPOZYME is given as an intravenous (IV) infusion once every 2 weeks - the dose is based on body weight.
    Doctor and patient icons with text stating XENPOZYME must always be administered by a trained healthcare provider
    Infusion bag and house icons with text stating Once you or your child starts receiving the maintenance dose, there is a potential option of receiving XENPOZYME at home if your doctor recommends it.
    What you should know before starting treatment
    • XENPOZYME dosage initiation or escalation, at any time during pregnancy, is not recommended.
      • If you are a female of reproductive potential, your doctor will verify your pregnancy status before starting treatment with XENPOZYME.
      • Use effective contraception during treatment with XENPOZYME and for 14 days after the last dose if XENPOZYME is discontinued.
      • If you are pregnant or plan to become pregnant, tell your doctor right away.
    • Your doctor will order a baseline liver enzyme level measurement for you or your child within 1 month prior to the start of treatment.
    • Prior to infusion, your doctor may decide to pretreat you or your child with anti-fever, anti-allergy, and/or steroid medications.

    Treatment with XENPOZYME takes place in 2 phases

    FIRST PHASE IS CALLED DOSE ESCALATION

    You or your child will start on a low dose that will gradually increase throughout the dose escalation phase. This will last at least 14 weeks for adults and at least 16 weeks for children.*

    Icon of dark blue ascending arrow above green stairs with white infusion bag enclosed

    Why dose escalation? Gradual dose escalation is essential and may reduce the risk of infusion-associated reactions and elevated liver enzyme levels when first starting treatment.

    Infusion bag and hospital icons

    Where does dose escalation take place? The dose escalation period takes place in a clinical setting to manage for the possibility of severe reactions.

    SECOND PHASE IS CALLED MAINTENANCE

    After dose escalation, the target maintenance dose is 3 mg/kg.

    Green triple chevron icon

    Why ongoing maintenance? In people with ASMD, the body is unable to make enough of the ASM enzyme; therefore, it is important to keep taking XENPOZYME every 2 weeks.

    Infusion bag and house icons

    Can infusions take place at home? Once you or your child starts receiving the maintenance dose, there is a potential option of receiving XENPOZYME at home if your doctor recommends it.

    *In clinical trials, all but 1 of the children completed the dose escalation up to the target maintenance dose of 3 mg/kg within 22 weeks.

    Thumbnail of XENPOZYME® (olipudase alfa-rpcp) Patient Dosing Guide

    Find more information inside the Patient Dosing Guide

    DOWNLOAD
    Monitoring for liver enzyme levels during infusions
    • During the dose escalation phase, your doctor will regularly order blood tests to monitor how the liver is working. If liver enzymes are elevated, the doctor may delay an infusion, repeat a dose, or lower the dose for the next infusion.
    • During the maintenance phase, upon reaching the recommended maintenance dose, testing for liver enzyme levels is recommended to be continued as part of routine clinical management of ASMD.

    What else do I need to know?

    Calendar icon
    Stay on track with treatment

    Make sure you set aside enough time in your calendar for regular, biweekly infusions.

    Infusion bag and hospital icons
    Missed infusions

    If you miss infusions, you may need to return to dose escalation. Dose escalation should take place in a clinical setting.

ASM=acid sphingomyelinase; ASMD=acid sphingomyelinase deficiency.

Want to receive more information on XENPOZYME?

SIGN UP
Icon depicting hand holding paper document
This way to personalized support

Get support
Icon of green paper and magnifying glass
Find helpful resources to guide you along the way
Browse resources

IMPORTANT SAFETY INFORMATION AND INDICATION

WARNING: SEVERE ALLERGIC REACTIONS

Allergic Reactions Including Anaphylaxis
Allergic reactions, including severe reactions that may be serious or life-threatening (known as anaphylaxis), have occurred during and after XENPOZYME treatment. Tell your healthcare provider right away if you develop any reactions, and seek immediate medical care if severe reactions occur. If a severe allergic reaction occurs, your doctor may decide to discontinue XENPOZYME immediately and provide appropriate medical care. Appropriate medical support measures may be administered, and you may require close observation during and after XENPOZYME administration.

WARNINGS AND PRECAUTIONS

Allergic Reactions (Including Anaphylaxis) and Infusion-Associated Reactions (IARs)
See Boxed WARNING for more information. Your doctor may decide to give you antihistamine, anti-fever, and/or steroid medications before your infusions. Signs of allergic reactions and infusion-associated reactions (IARs) included hives, itchy skin, skin redness, rash, swelling underneath the skin, tender bumps under the skin, and localized swelling, as well as headache, vomiting, nausea, fever, and diarrhea.

Reactions may occur during and/or after the infusion. Tell your healthcare provider right away if you experience any reactions. Your healthcare provider may slow or stop the infusion or may lower the next dose.

Elevated Transaminases Levels
XENPOZYME may be associated with elevated liver enzymes (known as transaminases) within 24 to 48 hours after infusion. Your doctor should check your liver enzyme levels with a blood test:

  • within one month before starting XENPOZYME;
  • within 72 hours before any infusion during the dose escalation phase, or before your next scheduled XENPOZYME infusion if you missed a dose.

Based on the results of your blood tests, your doctor may make changes to your dose or infusion schedule. Upon reaching the recommended maintenance dose, your doctor may continue to monitor your liver enzyme levels.

Risk to Unborn Babies
Starting or increasing the dose of XENPOZYME is not recommended in a pregnant female as it may cause harm (birth defects) to the developing baby. If you are pregnant or plan to become pregnant, tell your doctor right away. 

If you are a female of reproductive potential, your doctor will verify your pregnancy status before you start treatment with XENPOZYME. You should use effective contraception during XENPOZYME treatment and for 14 days after your last dose if XENPOZYME is discontinued.

ADVERSE REACTIONS

  • Most frequently reported adverse drug reactions in adults (incidence ≥10%) were headache, cough, diarrhea, low blood pressure, and redness in the eye.
  • Most frequently reported adverse drug reactions in pediatric patients (incidence ≥20%) were fever, cough, diarrhea, runny nose, abdominal pain, vomiting, headache, hives, nausea, rash, joint pain, itchy skin, fatigue, and sore throat.

INDICATION
XENPOZYME® (olipudase alfa-rpcp) is indicated for treatment of non–central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients.

Please see full Prescribing Information, including Boxed WARNING, for complete details.

IMPORTANT SAFETY INFORMATION AND INDICATION

WARNING: SEVERE ALLERGIC REACTIONS

Allergic Reactions Including Anaphylaxis
Allergic reactions, including severe reactions that may be serious or life-threatening (known as anaphylaxis), have occurred during and after XENPOZYME treatment. Tell your healthcare provider right away if you develop any reactions, and seek immediate medical care if severe reactions occur. If a severe allergic reaction occurs, your doctor may decide to discontinue XENPOZYME immediately and provide appropriate medical care. Appropriate medical support measures may be administered, and you may require close observation during and after XENPOZYME administration.

WARNINGS AND PRECAUTIONS

Allergic Reactions (Including Anaphylaxis) and Infusion-Associated Reactions (IARs)
See Boxed WARNING for more information. Your doctor may decide to give you antihistamine, anti-fever, and/or steroid medications before your infusions. Signs of allergic reactions and infusion-associated reactions (IARs) included hives, itchy skin, skin redness, rash, swelling underneath the skin, tender bumps under the skin, and localized swelling, as well as headache, vomiting, nausea, fever, and diarrhea.

Reactions may occur during and/or after the infusion. Tell your healthcare provider right away if you experience any reactions. Your healthcare provider may slow or stop the infusion or may lower the next dose.

Elevated Transaminases Levels
XENPOZYME may be associated with elevated liver enzymes (known as transaminases) within 24 to 48 hours after infusion. Your doctor should check your liver enzyme levels with a blood test:

  • within one month before starting XENPOZYME;
  • within 72 hours before any infusion during the dose escalation phase, or before your next scheduled XENPOZYME infusion if you missed a dose.

Based on the results of your blood tests, your doctor may make changes to your dose or infusion schedule. Upon reaching the recommended maintenance dose, your doctor may continue to monitor your liver enzyme levels.

Risk to Unborn Babies
Starting or increasing the dose of XENPOZYME is not recommended in a pregnant female as it may cause harm (birth defects) to the developing baby. If you are pregnant or plan to become pregnant, tell your doctor right away. 

If you are a female of reproductive potential, your doctor will verify your pregnancy status before you start treatment with XENPOZYME. You should use effective contraception during XENPOZYME treatment and for 14 days after your last dose if XENPOZYME is discontinued.

ADVERSE REACTIONS

  • Most frequently reported adverse drug reactions in adults (incidence ≥10%) were headache, cough, diarrhea, low blood pressure, and redness in the eye.
  • Most frequently reported adverse drug reactions in pediatric patients (incidence ≥20%) were fever, cough, diarrhea, runny nose, abdominal pain, vomiting, headache, hives, nausea, rash, joint pain, itchy skin, fatigue, and sore throat.

INDICATION
XENPOZYME® (olipudase alfa-rpcp) is indicated for treatment of non–central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients.

Please see full Prescribing Information, including Boxed WARNING, for complete details.